Shopping Cart
0 items
 
Total Visitors

GLUCOBAY 50 mg -BAYER

GLUCOBAY 50 mg -BAYER
For More Images Check Below
Availability: In Stock
Offer: US$ 0.45Per pill
Manufacturer: AVENTIS

Available Options:
GLUCOBAY 50MG-BAYERS
100
$90.00
Add Cart
GLUCOBAY 50MG-BAYERS
150
$115.00
Add Cart
GLUCOBAY 50MG-BAYERS
300
$150.00
Add Cart
GLUCOBAY 50MG-BAYERS
500
$225.00
Add Cart

 

Indications

Glucobay is recommended for the treatment of non-insulin dependent (NIDDM) diabetes mellitus in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.

 

Mode of action

Glucobay is a competitive inhibitor of intestinal alpha-glucosidases with maximum specific inhibitory activity against sucrase. Under the influence of Glucobay, the digestion of starch and sucrose into absorbable monosaccharides in the small intestine is dose-dependently delayed. In diabetic subjects, this results in a lowering of postprandial hyperglycaemia and a smoothing effect on fluctuations in the daily blood glucose profile.

In contrast to sulphonylureas Glucobay has no stimulatory action on the pancreas.

Treatment with Glucobay also results in a reduction of fasting blood glucose and to modest changes in levels of glycated haemoglobin (HbA1, HbA1c). The changes may be a reduction or reduced deterioration in HbA1 or HbA1c levels, depending upon the patient's clinical status and disease progression. These parameters are affected in a dose-dependent manner by Glucobay.

Following oral administration, only 1-2% of the active inhibitor is absorbed.

 

 

4.2 Posology and method of administration

Posology

Owing to the great individual variation of glucosidase activity in the intestinal mucosa, there is no fixed dosage regimen, and patients should be treated according to clinical response and tolerance of intestinal side-effects.

 

Adults

The recommended initial dose is 50 mg three times a day. However, some patients may benefit from more gradual initial dose titration to minimise gastrointestinal side-effects. This may be achieved by initiating treatment at 50 mg once or twice a day, with subsequent titration to a three times a day regimen.

If after six to eight weeks' treatment patients show an inadequate clinical response, the dosage may be increased to 100 mg three times a day. A further increase in dosage to a maximum of 200 mg three times a day may occasionally be necessary.

If distressing complaints develop in spite of strict adherence to the diet, the dose should not be increased further and if necessary should be reduced according to the severity of the side-effects and the clinical judgment of the prescriber.

Glucobay is intended for continuous long-term treatment.

 

Elderly

No modification of the normal adult dosage regimen is necessary.

 

Paediatric population

The efficacy and safety of Glucobay in children and adolescents have not been established. Glucobay is not recommended for patients under the age of 18 years.

 

Method of administration

Glucobay tablets are taken orally and should be chewed with the first mouthful of food, or swallowed whole with a little liquid directly before the meal.

 
There are no additional images for this product.
Tags: GLUCOBAY,